Furthermore, recent evidence obtained in preclinical models of different cancers, including HNSCC, demonstrate that Cetuximab can induce immunogenic cell death, i.e., a type of cell death involving the release of damage-associated molecular patterns (DAMPs) capable to trigger the generation of CD8+ T lymphocytes and lead to tumor-specific immunological memory (158, 159). The gene discussed is CD8A; the disease is cancer.